naproxen

(redirected from Vimovo)
Also found in: Dictionary, Thesaurus, Encyclopedia.

naproxen

 [nah-prok´sen]
a nonsteroidal antiinflammatory drug that is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory activity; used for treatment of rheumatoid arthritis, osteoarthritis, gout, calcium pyrophosphate deposition disease, fever, and dysmenorrhea, and in the prophylaxis and suppression of vascular headache; administered orally or rectally, as the base or the sodium salt.

naproxen

/na·prox·en/ (nah-prok´sen) a nonsteroidal anti-inflammatory drug used as the base or the sodium salt in the treatment of pain, inflammation, arthritis, gout, calcium pyrophosphate deposition disease, fever, and dysmenorrhea and in the prophylaxis and suppression of vascular headache.

naproxen

(nə-prŏk′sən)
n.
A nonsteroidal anti-inflammatory drug, C14H14O3, used to treat fever and pain.

naproxen

[naprok′sən]
a nonsteroidal antiinflammatory agent.
indications It is prescribed for the relief of fever, migraine headache, inflammatory symptoms of rheumatoid arthritis and osteoarthritis, and mild to moderate pain and for treatment of primary dysmenorrhea, ankylosing spondylitis, tendinitis, bursitis, and acute gout.
contraindications Impaired renal function, GI disease, or known hypersensitivity to this drug, to aspirin, or to nonsteroidal antiinflammatory drugs prohibits its use.
adverse effects Among the more serious adverse effects are GI disorders and peptic ulcers. Dizziness, rashes, and tinnitus commonly occur. This drug interacts with many other drugs.

naproxen

Naprosyn® Therapeutics An oral NSAID excreted through the kidney, breast milk, which crosses the placental barrier. See NSAIDs.

naproxen

A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID). Brand names are Naprosyn, Nycopren, Synflex and, formulated with the prostaglandin drug MISOPROSTOL, Napratec.

naproxen

non-steroidal anti-inflammatory drug used to control pain and inflammation in rheumatoid disease, musculoskeletal disorders and acute gout

naproxen

a propionic acid derivative with analgesic, antipyretic and anti-inflammatory activity (a nonsteroidal anti-inflammatory agent); its use is associated with gastroduodenal ulceration in dogs.
References in periodicals archive ?
Following issue, VIMOVO is expected to be listed in the US FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, concluded the company.
In a single pill, Vimovo provides a proven pain reliever with a built-in PPI for arthritis patients at-risk for NSAID-associated gastric ulcers," said Howard Hutchinson, M.
The US company is entitled to another milestone payment of USD25m if Vimovo gets marketing approval, including pricing and reimbursement approval, in a major market outside the USA.
In conjunction, this will be the 12 US patent to be listed in the Orange Book for VIMOVO, according to the company.
According to the company, it plan to list the US patent in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, reflecting the 11th US patent in the Orange Book for VIMOVO.
VIMOVO is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
VIMOVO is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID) and immediate-release esomeprazole, a stomach acid-reducing proton pump inhibitor (PPI) for adults aged over 18 years.
The USPTO's Notice of Allowance for US patent application number 14/045,156 entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" covers Horizon and POZEN's (NASDAQ:POZN) US approved product VIMOVO (naproxen / esomeprazole magnesium) delayed release tablets.
M2 PHARMA-January 6, 2014-Horizon Pharma launches VIMOVO in US
M2 EQUITYBITES-August 14, 2014-Horizon Pharma wins additional notice of allowance patent in the US for VIMOVO Delayed Release Tablets
M2 PHARMA-January 3, 2014-Horizon Pharma's Horizon-labelled VIMOVO now available to US physicians
M2 EQUITYBITES-January 6, 2014-Horizon Pharma launches VIMOVO in US